TNSN07141A1 - Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms - Google Patents
Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fmsInfo
- Publication number
- TNSN07141A1 TNSN07141A1 TNP2007000141A TNSN07141A TNSN07141A1 TN SN07141 A1 TNSN07141 A1 TN SN07141A1 TN P2007000141 A TNP2007000141 A TN P2007000141A TN SN07141 A TNSN07141 A TN SN07141A TN SN07141 A1 TNSN07141 A1 TN SN07141A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methylpiperazin
- ylamino
- benzamide
- pyrimidin
- ylmethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61974404P | 2004-10-18 | 2004-10-18 | |
| PCT/AU2005/001602 WO2006042362A1 (en) | 2004-10-18 | 2005-10-17 | Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN07141A1 true TNSN07141A1 (en) | 2008-11-21 |
Family
ID=36202610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2007000141A TNSN07141A1 (en) | 2004-10-18 | 2007-04-17 | Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms |
Country Status (19)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009058968A2 (en) * | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| EP3246046A4 (en) * | 2015-01-13 | 2018-12-05 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) * | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| DE60212836T2 (de) * | 2001-05-16 | 2007-01-25 | Gpc Biotech Ag | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
| US20060052387A1 (en) * | 2002-06-26 | 2006-03-09 | Marsh Clay B | Organic compounds |
-
2005
- 2005-10-17 JP JP2007535954A patent/JP2008516898A/ja active Pending
- 2005-10-17 RU RU2007118420/15A patent/RU2007118420A/ru unknown
- 2005-10-17 NZ NZ554009A patent/NZ554009A/en not_active IP Right Cessation
- 2005-10-17 CN CNA2005800338341A patent/CN101035535A/zh active Pending
- 2005-10-17 KR KR1020077008716A patent/KR20070083705A/ko not_active Ceased
- 2005-10-17 DE DE602005025514T patent/DE602005025514D1/de not_active Expired - Lifetime
- 2005-10-17 AU AU2005297321A patent/AU2005297321A1/en not_active Abandoned
- 2005-10-17 BR BRPI0517083-4A patent/BRPI0517083A/pt not_active IP Right Cessation
- 2005-10-17 WO PCT/AU2005/001602 patent/WO2006042362A1/en not_active Ceased
- 2005-10-17 EP EP05793868A patent/EP1804800B1/en not_active Expired - Lifetime
- 2005-10-17 AT AT05793868T patent/ATE492277T1/de not_active IP Right Cessation
- 2005-10-17 US US11/576,967 patent/US20080255139A1/en not_active Abandoned
- 2005-10-17 CA CA002580976A patent/CA2580976A1/en not_active Abandoned
- 2005-10-17 MX MX2007004660A patent/MX2007004660A/es unknown
-
2007
- 2007-03-20 ZA ZA200702316A patent/ZA200702316B/xx unknown
- 2007-04-10 IL IL182419A patent/IL182419A0/en unknown
- 2007-04-17 TN TNP2007000141A patent/TNSN07141A1/fr unknown
- 2007-04-25 MA MA29848A patent/MA28946B1/fr unknown
- 2007-05-15 NO NO20072501A patent/NO20072501L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007118420A (ru) | 2008-11-27 |
| ATE492277T1 (de) | 2011-01-15 |
| MA28946B1 (fr) | 2007-10-01 |
| JP2008516898A (ja) | 2008-05-22 |
| DE602005025514D1 (de) | 2011-02-03 |
| WO2006042362A1 (en) | 2006-04-27 |
| KR20070083705A (ko) | 2007-08-24 |
| BRPI0517083A (pt) | 2008-09-30 |
| CN101035535A (zh) | 2007-09-12 |
| EP1804800A4 (en) | 2008-03-19 |
| NZ554009A (en) | 2010-09-30 |
| CA2580976A1 (en) | 2006-04-27 |
| US20080255139A1 (en) | 2008-10-16 |
| IL182419A0 (en) | 2007-09-20 |
| MX2007004660A (es) | 2007-10-17 |
| EP1804800A1 (en) | 2007-07-11 |
| ZA200702316B (en) | 2008-09-25 |
| EP1804800B1 (en) | 2010-12-22 |
| AU2005297321A1 (en) | 2006-04-27 |
| NO20072501L (no) | 2007-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1332137E (pt) | Tratamento de tumores estromais gastrintestinais | |
| MX391723B (es) | Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton. | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| HUE034712T2 (hu) | Amidszármazék és gyógyszer | |
| PE20121476A1 (es) | Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| TWI347186B (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| MY148878A (en) | Stabilized amorphous forms of imatinib mesylate | |
| NO20075022L (no) | (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav | |
| WO2008059551A3 (en) | Process for the preparation of imatinib and intermediates thereof | |
| NZ590177A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
| MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
| PE20141337A1 (es) | Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida | |
| IL182419A0 (en) | Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms | |
| IL162983A (en) | Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis | |
| ES2421587T3 (es) | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica | |
| JP2008542390A5 (cg-RX-API-DMAC7.html) | ||
| IL171927A0 (en) | Use of tyrosine kinase inhibitor to treat diabetes | |
| HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti | |
| RU2015120692A (ru) | Производное 6-оксо-1,6-дигидро-пиридизина для применения в лечении гепатоцеллюлярной карциномы (гцк) | |
| TNSN05304A1 (en) | Use of tyrosine kinase inhibitor to treat diabetes | |
| JP2008516898A5 (cg-RX-API-DMAC7.html) |